SANTA CLARA, Calif.--(BUSINESS WIRE)--A recent study conducted by global industry analysts Frost & Sullivan clarifying the state and dynamics of genomic technology adoption and utilization in the U.S. has concluded that microarray technology—the cornerstone of two decades of discovery—will remain relevant to the advancement of biomedical research and translational medicine in the future. Moreover, while excitement for next-generation sequencing (NGS) remains justifiably high, genomics research remains sustained by mainstay platforms, like those manufactured by Affymetrix, Inc. (NASDAQ:AFFX)1.
